Homology Medicines Acquired by
Ticker: QTTB · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1661998
| Field | Detail |
|---|---|
| Company | Homology Medicines, Inc. (QTTB) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | medium |
| Pages | 12 |
| Reading Time | 14 min |
| Key Dollar Amounts | $0.0001, $15 million, $360 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, biotech
TL;DR
Homology Medicines is being acquired by . Deal expected to close Q2 2024.
AI Summary
Homology Medicines, Inc. announced on March 11, 2024, that it has entered into a definitive agreement to be acquired by''. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions. This acquisition will combine Homology Medicines' gene therapy platform with ''s capabilities.
Why It Matters
This acquisition signifies a consolidation in the gene therapy space, potentially impacting the development and accessibility of treatments for rare genetic diseases.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and the exact terms and potential impact on Homology Medicines' pipeline are not fully detailed.
Key Players & Entities
- Homology Medicines, Inc. (company) — The company filing the 8-K and being acquired.
- March 11, 2024 (date) — The date of the report and the earliest event reported.
- second quarter of 2024 (date) — Expected closing period for the acquisition.
FAQ
What is the name of the acquiring company?
The filing does not explicitly state the name of the acquiring company, referring to it as ''.
When is the acquisition expected to close?
The acquisition is expected to close in the second quarter of 2024.
What is the primary business of Homology Medicines, Inc.?
Homology Medicines, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
What is the state of incorporation for Homology Medicines, Inc.?
Homology Medicines, Inc. is incorporated in Delaware.
What is the principal executive office address for Homology Medicines, Inc.?
The principal executive offices are located at One Patriots Park, Bedford, MA 01730.
Filing Stats: 3,501 words · 14 min read · ~12 pages · Grade level 16.1 · Accepted 2024-03-11 07:32:56
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FIXX The Nasdaq
- $15 million — derived from the selected companies of $15 million to $360 million for Q32 utilizing the o
- $360 million — he selected companies of $15 million to $360 million for Q32 utilizing the observed 25th per
Filing Documents
- d806643d8k.htm (8-K) — 53KB
- 0001193125-24-064315.txt ( ) — 178KB
- fixx-20240311.xsd (EX-101.SCH) — 3KB
- fixx-20240311_lab.xml (EX-101.LAB) — 17KB
- fixx-20240311_pre.xml (EX-101.PRE) — 11KB
- d806643d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HOMOLOGY MEDICINES, INC. Date: March 11, 2024 By: /s/ Paul G. Alloway, Ph.D. Name: Paul G. Alloway, Ph.D. Title: President, Chief Operating Officer and Secretary